OTT is proud to have assembled a world-class Board of Directors with extensive experience and expertise in the pharmaceutical industry. Comprising seasoned professionals and leaders in their respective fields, our board members bring a wealth of knowledge and strategic vision to guide our company's growth and success.
Our board consists of distinguished individuals with deep insight, encompassing drug discovery & development, commercialization, regulatory affairs, corporate partnerships and IPOs. Their collective expertise allows us to navigate the complex landscape of the pharmaceutical sector, ensuring sound decision-making and effective execution of our business strategies.
Drawing upon their expertise, our board members play a vital role in shaping OTT's vision and providing valuable guidance to our management team. They bring a wealth of industry relationships, strategic perspectives, and a commitment to advancing the development of innovative cancer therapies for patients in need.
With their proven track records and dedication to excellence, our board members exemplify high standards of corporate governance and leadership. Their invaluable contributions help position OTT as a trusted and forward-thinking organisation, driving us towards our mission of transforming the landscape of healthcare through breakthrough drug development and strategic partnerships.
Our Scientific Leadership Team comprises a group of distinguished experts who are at the forefront of scientific innovation and drug development. With their knowledge and experience, they drive our research and development efforts, shaping the future of medicine.
Our Scientific Leadership Team consists of accomplished scientists, researchers, and medical professionals who bring a diverse range of expertise to our organization. They possess deep understanding and specialization in biochemistry, genomics, clinical genetics, structural biology and cancer research, allowing us to tackle the most challenging medical needs.
The Scientific Leadership Team's experience, coupled with their commitment to scientific excellence, enables us to identify and develop novel therapies that have the potential to make a significant impact on patients' lives. Together, we are pushing the boundaries of innovation and working towards a future where unmet medical needs are addressed through groundbreaking treatments.
OTT operates on a highly effective and financially prudent business model that positions us as a compelling investment opportunity in the pharmaceutical industry.
Our business model is built upon the strategic integration of drug discovery & development expertise, collaboration with research institutions, and a focus on securing corporate partnerships with pharmaceutical companies. By leveraging these key elements, we have created a streamlined and efficient approach to bringing novel drugs to market.
At the core of our business model is our ability to identify promising drug candidates with first-in-class profiles that have the potential to become leading oncology therapeutics.
Our emphasis on collaboration and strategic partnerships enables us to access a global network of research institutions, biotech companies, and academic experts. This collaborative approach minimises costs and expands our scientific knowledge base, providing us with a competitive advantage in the industry.
Through our business model, we de-risk the drug development process by advancing compounds to a stage where they become attractive to larger pharmaceutical companies. This strategy not only optimises our resources but also positions us for corporate deals and licensing agreements, ensuring a significant return on investment for our shareholders.
OTT's strategy as a route to market is through corporate deals, licensing the rights for each product to companies which are in the sector. This could be done on a world-wide level with multinational companies, or at a regional or even national level with local companies, in return for royalties and milestone payments. The Company intends to enter into industry partnerships early, which minimises the need for capital as the high drug development costs are incurred in late stage clinical trials. The strategy of the company in terms of commercialisation means that it does not need to set up and fund a sales and marketing organisation and can access directly the substantial worldwide selling capabilities and structures of the big pharma companies. This strategy and options are in-line with the Company's focus on maintaining a low-cost base and avoiding hiring numerous commercial people. Importantly, as a validation for this rationale, the strategy capitalises on the trends in the pharmaceutical industry for licensing new products and acquisitions.
The global pharmaceutical drugs market was estimated at $1.14 trillion in 2022 and is expected to reach $1.64 trillion in 2026 at a CAGR of 9.5%, according to a report by Research And Markets published in September 2022.
Based on information from Statista (2023), The Oncology Drugs market is witnessing a remarkable surge, with a projected revenue of US$188 billion by 2023, indicating an impressive annual growth rate of 14%, and an estimated market volume of US$361 billion by 2028. This surge reflects the growing significance of addressing cancer, one of the leading health challenges worldwide.
Cancer, with its intricate interplay of genetic factors and external agents, continues to impact millions of individuals across all age groups, leading to a significant rise in new cancer cases each year. In 2020, cancer accounted for nearly 10 million deaths globally, and this number is expected to surpass 16 million by 2040.
The oncology market has witnessed significant developments since January 2021, with a record-breaking 30 novel active substances (NASs) launched globally in the year. A remarkable 159 NASs have been introduced since 2012, with 104 launched in the last five years alone. In the U.S., 83 unique new cancer medicines were launched in the past five years, with some receiving approvals for multiple indications. Notably, the time from patent filing to product launch for the 2020 NAS cohort for oncology products reduced to 8.5 years in 2021.
Accelerated approvals, orphan, and breakthrough designations have become increasingly common for oncology drugs, facilitating faster access to innovative therapies. The European Medicines Agency (EMA) approved ten new oncology NASs in 2021, comprising six small molecules and four biologics.
Emerging biopharma companies have significantly contributed to the oncology pipeline, accounting for 68% of the total in 2021, a substantial increase from 45% a decade ago.
While oncology trials demonstrate higher complexity compared to other therapeutic areas, they often require fewer subjects for successful completion. The number of subjects in oncology clinical trials is growing, while accelerated approvals tend to rely on a smaller number of subjects.
OTT understands the importance of addressing the unmet needs in oncology, and we are dedicated to advancing novel drug candidates that can revolutionise cancer therapy. By leveraging our drug discovery expertise and strategic collaborations, we aim to meet the unmet need for effective and personalised oncology treatments.
OTT's new approach for treating cancer is by targeting a specific protein complex called the Anaphase-Promoting Complex/Cyclosome (APC/C). This complex plays a crucial role in regulating the cell division process. When the cell divides, the chromosomes need to separate properly to ensure the formation of healthy daughter cells. The APC/C helps control this process by marking certain proteins for degradation, allowing the chromosomes to divide correctly.
In cancer, there can be abnormalities in cell division, leading to uncontrolled growth and the formation of tumours. Inhibiting the APC/C represents a promising strategy to disrupt the abnormal cell division seen in cancer cells. OTT's platform technology drug candidates are a group of compounds called N-benzyl-alpha-aminoamides, which have been identified as potential inhibitors of the APC/C. These compounds were tested in laboratory experiments using cancer cells, and the results showed that they can interfere with the function of the APC/C and inhibit its activity.
By inhibiting the APC/C, these compounds have the potential to disrupt the abnormal cell division in cancer cells and potentially slow down tumour growth. This mechanism of action is considered exciting because it targets a specific protein complex involved in the cell cycle, which is a fundamental process for cancer cell proliferation.
Targeting the APC/C with OTT's molecules is a novel and promising approach for developing new oncology treatments. It opens up possibilities for further investigation and the development of drugs that specifically target this mechanism to combat cancer.
The lead product in development has shown good efficacy and safety in lab tests. Three additional molecules which OTT owns, demonstrate the company's commitment to exploring and expanding its pipeline beyond the lead drug. By investigating structurally related compounds, the company aims to identify and develop a range of potential drug candidates with varying properties and therapeutic profiles. Each of these molecules represents a potential avenue for future research, optimisation, and clinical evaluation in the pursuit of novel cancer treatments.
Summary
The Company’s Code of Conduct policy will be drafted and agreed upon by the new Board members to ensure a comprehensive framework for ethical behaviour and corporate responsibility.
Our Code of Conduct establishes the principles and values that guide our actions and interactions, reflecting the company's commitment to achieving its mission and objectives. It governs the behaviour of all individuals associated with the company, including employees, officers, directors, and stakeholders.
The following key principles form the foundation of our Code of Conduct:
• Integrity and Transparency
• Professionalism
• Continuous Improvement and Innovation
• Respect and Dignity
• Commitment to Quality
• Reliability and Consistency
• Customer Dedication
• Social and Environmental Responsibility
By adhering to this Code of Conduct, the Directors of OTT exemplify their commitment to maintaining high standards of ethical conduct and corporate responsibility. It is through our collective adherence to these principles that we build trust, foster strong relationships, and achieve sustainable success.
Global Reporting Initiative
The Company recognises the significance of the Global Reporting Initiative (GRI) Reporting Framework in enhancing transparency and accountability. Through GRI, we aim to provide useful information that goes beyond financial statements, allowing stakeholders to gain a comprehensive understanding of how we create value in the short, medium, and long-term.
We are committed to integrating non-financial aspects into our reporting to showcase the interconnectedness between strategy, governance, environmental considerations, and social considerations. By doing so, we can effectively communicate our approach to value creation and demonstrate our commitment to sustainable practices.
The Directors understand the importance of transparent and forward-looking reporting. To achieve this, we will:
• Report on Categories of Capital
• Showcase Tangible and Intangible Assets
• Report on Non-Financial Performance
• Uphold Ethical Practices
• Continuously Improve Perception
• Link Strategy with Operations
By adopting the GRI Reporting Framework and adhering to its principles, the Directors of OTT are dedicated to providing comprehensive and meaningful information to our stakeholders. We believe that transparent reporting not only enhances accountability but also fosters trust and enables informed decision-making.
Corporate Social Responsibility
Corporate Social Responsibility (CSR) is a fundamental aspect of our business philosophy. We recognise that our success is not solely determined by financial performance, but also by our impact on society and the environment. We are committed to integrating CSR principles into our operations and ensuring that our business practices contribute positively to the well-being of stakeholders and the communities we serve.
Our approach to CSR encompasses several key areas: Environmental Stewardship, Social Impact, Ethical Business Practices, Stakeholder Engagement and Philanthropy and Community Investment.
By embracing CSR principles, we demonstrate our commitment to responsible business practices and sustainable development. We believe that by integrating economic, social, and environmental considerations, we can create long-term value for our stakeholders while contributing to a more equitable and sustainable future.
Search investors section
Corporate structure
Oxford Target Therapeutics Ltd is a UK-based biotech company incorporated in England with company number 13886983. Our registered office address is Bioinnovation Hub, Tonge Building Oxford Brookes University, Gipsy Lane, Headington Campus, Oxford, Oxfordshire OX3 0BP, U.K.
Company history
Founded in Oxford, UK, Oxford Target Therapeutics (OTT) is a biotech company focused on revolutionising cancer therapy. Leveraging many years of pioneering research and its strategic collaborations with research institutions and a seasoned team of experts, OTT is driven to uncover novel drug targets and transform them into effective anticancer agents.
Over the years, the company has achieved several significant milestones: Founding and Early Research focused on elucidating the role of a new mechanism in tumour development, Target Identification and Validation provided compelling evidence for the therapeutic potential of modifying this critical pathway, Preclinical Drug Development with a series of potent small molecules designed and optimised disrupting tumour cell proliferation and Proof-of-Concept Studies with OTT's lead compound demonstrating remarkable efficacy in inhibiting tumour growth and inducing cancer cell death.
The company was founded by the academic researchers as a spin-off by Oxford Brooks University in the U.K.
